Global Programme on Tuberculosis & Lung Health
The WHO Global Programme on Tuberculosis & Lung Health works towards the goal of a world free of TB, with zero deaths, disease and suffering due to the disease. The team’s mission is to lead and guide the global effort to end the TB epidemic through universal access to people-centred prevention and care, multisectoral action and innovation.
Types of drug-resistant TB
Mono-resistance: resistance to one first-line anti-TB drug only
Poly-resistance: resistance to more than one first-line anti-TB drug, other than both isoniazid and rifampicin
Multidrug resistance (MDR): resistance to at least both isoniazid and rifampicin
Extensive drug resistance (XDR): resistance to any fluoroquinolone, and at least one of three second-line injectable drugs (capreomycin, kanamycin and amikacin), in addition to multidrug resistance
Rifampicin resistance (RR): resistance to rifampicin detected using phenotypic or genotypic methods, with or without resistance to other anti-TB drugs. It includes any resistance to rifampicin, in the form of mono-resistance, poly-resistance, MDR or XDR.